14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LH vs HOLX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LH vs HOLX. Trailing 12-month operating profitability (LH 11.2% vs HOLX 23.0%) and valuation multiples (LH 18.7x vs HOLX 20.1x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment37.4% of Rev ($1.54B)
90D Engineering Disclosures0 Published
Investor FAQ LH vs HOLX Key Questions & Quantitative Answers
As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Labcorp Holdings Inc. (LH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). LH carries a Unified Composite Score of 44.1/100 (HOLD) at $367.13 (18.7x Forward P/E, 11.2% operating margin), whereas HOLX carries 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin). Technically, LH sits in a Markup phase (RSI 62.3, CONSOLIDATION options structure) and HOLX sits in a Neutral phase (RSI 69.0, UNCLASSIFIED options structure).
LH leads the Growth & Scale pillar: LH posts +6.9% YoY revenue growth and +3.2% YoY earnings growth on $14.6B TTM revenue (29.0% gross margin, 11.2% operating margin), compared with HOLX at +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin). On trailing 12-month operating scale, LH generates $14.6B in USD-normalized revenue versus $4.13B for HOLX. In operating R&D and SG&A reinvestment, LH deploys 17.8% of Rev ($2.60B) (0 90-day corporate R&D disclosures) versus 37.4% of Rev ($1.54B) (0 disclosures) for HOLX.
LH screens cheaper on headline valuation multiples. LH trades at 18.7x Forward P/E, 30.2x Trailing P/E, 1.21x PEG, and 2.5x EV/Revenue (8.8% FCF margin), whereas HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LH (11.4% ROE) versus HOLX (10.9% ROE) capital efficiency.
In options market volatility and institutional positioning, LH carries 76.5% implied volatility (44th %ile, Balanced (25th–60th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.33β · 35% Vol realized risk). By comparison, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.